PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer

METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline

How smarter therapies can help metastatic breast cancer patients – and why we need more!

Why we need MBC research more than ever

At METUPUK, we campaign for new and better therapies for patients with secondary breast cancer. One of our recent campaigns, #TrodelvyNow helped to make a new type of drug, Trodelvy (sacituzumab govitecan) available for SBC patients in the UK. Scientist and METUPUK volunteer, Helen, explains how Trodelvy works and why it’s important that more drugs like this get to patients urgently.